BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19369227)

  • 1. Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.
    Kim SW; Rai D; McKeller MR; Aguiar RC
    Blood; 2009 Jun; 113(24):6153-60. PubMed ID: 19369227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
    Smith PG; Wang F; Wilkinson KN; Savage KJ; Klein U; Neuberg DS; Bollag G; Shipp MA; Aguiar RC
    Blood; 2005 Jan; 105(1):308-16. PubMed ID: 15331441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
    Suhasini AN; Wang L; Holder KN; Lin AP; Bhatnagar H; Kim SW; Moritz AW; Aguiar RCT
    Leukemia; 2016 Mar; 30(3):617-626. PubMed ID: 26503641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
    Kim DU; Kwak B; Kim SW
    Biochem Biophys Res Commun; 2019 Jan; 508(3):825-831. PubMed ID: 30528730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
    Kim SW; Rai D; Aguiar RC
    Clin Cancer Res; 2011 Nov; 17(21):6723-32. PubMed ID: 21742807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
    Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
    Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
    Szydlowski M; Kiliszek P; Sewastianik T; Jablonska E; Bialopiotrowicz E; Gorniak P; Polak A; Markowicz S; Nowak E; Grygorowicz MA; Prochorec-Sobieszek M; Szumera-Cieckiewicz A; Malenda A; Lech-Maranda E; Warzocha K; Juszczynski P
    Blood; 2016 Feb; 127(6):739-48. PubMed ID: 26585955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 9. SYK regulates mTOR signaling in AML.
    Carnevale J; Ross L; Puissant A; Banerji V; Stone RM; DeAngelo DJ; Ross KN; Stegmaier K
    Leukemia; 2013 Nov; 27(11):2118-28. PubMed ID: 23535559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.
    Chen L; Monti S; Juszczynski P; Ouyang J; Chapuy B; Neuberg D; Doench JG; Bogusz AM; Habermann TM; Dogan A; Witzig TE; Kutok JL; Rodig SJ; Golub T; Shipp MA
    Cancer Cell; 2013 Jun; 23(6):826-38. PubMed ID: 23764004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas.
    Hatton O; Phillips LK; Vaysberg M; Hurwich J; Krams SM; Martinez OM
    J Biol Chem; 2011 Oct; 286(43):37368-78. PubMed ID: 21908615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.
    Hatton O; Lambert SL; Phillips LK; Vaysberg M; Natkunam Y; Esquivel CO; Krams SM; Martinez OM
    Am J Transplant; 2013 Apr; 13(4):883-890. PubMed ID: 23398911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.
    Chen L; Monti S; Juszczynski P; Daley J; Chen W; Witzig TE; Habermann TM; Kutok JL; Shipp MA
    Blood; 2008 Feb; 111(4):2230-7. PubMed ID: 18006696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-124 regulates glucocorticoid sensitivity by targeting phosphodiesterase 4B in diffuse large B cell lymphoma.
    Kim J; Jeong D; Nam J; Aung TN; Gim JA; Park KU; Kim SW
    Gene; 2015 Mar; 558(1):173-80. PubMed ID: 25576220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.
    Gururajan M; Dasu T; Shahidain S; Jennings CD; Robertson DA; Rangnekar VM; Bondada S
    J Immunol; 2007 Jan; 178(1):111-21. PubMed ID: 17182546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
    Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
    Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoralidin inhibits LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IκB signaling pathways.
    Chiou WF; Don MJ; Liao JF; Wei BL
    Eur J Pharmacol; 2011 Jan; 650(1):102-9. PubMed ID: 20951127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct role of spleen tyrosine kinase in the early phosphorylation of inhibitor of kappaB alpha via activation of the phosphoinositide-3-kinase and Akt pathways.
    Lee YG; Chain BM; Cho JY
    Int J Biochem Cell Biol; 2009 Apr; 41(4):811-21. PubMed ID: 18775507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
    Buchner M; Fuchs S; Prinz G; Pfeifer D; Bartholomé K; Burger M; Chevalier N; Vallat L; Timmer J; Gribben JG; Jumaa H; Veelken H; Dierks C; Zirlik K
    Cancer Res; 2009 Jul; 69(13):5424-32. PubMed ID: 19549911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.